SecBot SecBot
PRESS-RELEASE ·Filed Apr 2, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Traders should monitor the 1H2026 NDA submission and 3Q2026 CHAPTER-3 topline data as primary catalysts; current financials are secondary. Cash runway appears sufficient for now, but future dilution risk increases if commercialization is delayed or approval denied.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$28.56
T+0 close · Apr 2, 2026 · via day close
Latest settled
+21.08%
T+60 · $34.58
Vs SPY
+6.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 2 $28.56entry
  2. T+1 · 8mo ago −0.67%α −1.14% · $28.37
  3. T+5 · 7mo ago −6.76%α −10.38% · $26.63
  4. T+20 · 7mo ago +8.58%α −1.30% · $31.01
  5. T+60 · 5mo ago +21.08%α +6.92% · $34.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus) with no revenue, typical for a pre-revenue biotech. The focus remains on upcoming catalysts: NDA submission for deucrictibant IR in 1H2026 and topline data from the CHAPTER-3 pivotal trial in 3Q2026. Cash runway of €292M supports operations through key inflection points.

Key Financial Metrics

EPS
−$0.60
est −$0.62 · +3.2%
Revenue
$0.00
est $0.00 · 0.0%
Rating
in line

Key Facts

  • EPS of $-0.60 vs. consensus of $-0.62 (3% beat), revenue $0 in line with expectations
  • Cash and cash equivalents: €292 million as of December 31, 2025
  • NDA submission for deucrictibant IR (on-demand HAE treatment) on track for 1H2026
  • Topline data from CHAPTER-3 trial (prophylactic HAE treatment) expected in 3Q2026
  • Enrollment ongoing in CREAATE trial for AAE-C1INH, a potential expansion indication

Financial Impact

Minimal near-term financial impact; company remains pre-revenue with expected losses continuing into 2026

epscashr&d_expense

Risk Factors

  • Regulatory risk around NDA approval for deucrictibant IR in 2026
  • Clinical risk in CHAPTER-3 and CREAATE trials failing to replicate RAPIDe-3 success
  • Dilution risk if additional funding is needed beyond 2026

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3267207

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 2, 2026